LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Not Yet Opened 04-08 16:08:19

18.690

+2.010

+12.05%

High18.780	Low16.680	Vol10.00M
Open16.680	D1 Closing16.680	Amplitude12.59%
Mkt Cap8.34B	Tradable Cap8.34B	Total Shares446.00M
T/O180.79M	T/O Rate2.24%	Tradable Shares446.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":18.69,"timestamp":1775635699006,"preClose":16.68,"halted":0,"volume":10000519,"delay":0,"changeRate":0.12050359712230226,"floatShares":446000000,"shares":446000000,"eps":-0.6765809589448787,"marketStatus":"Not Yet Opened","change":2.01,"latestTime":"04-08 16:08:19","open":16.68,"high":18.78,"low":16.68,"amount":180791178,"amplitude":0.125899,"askPrice":18.69,"askSize":1000,"bidPrice":18.51,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.6524992637959931,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775698200000},"marketStatusCode":0,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":16.68,"openAndCloseTimeList":[[1775611800000,1775620800000],[1775624400000,1775635200000]],"volumeRatio":2.65104,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"1185906956","title":"Laekna-B Maintains 446.47 Million Outstanding Shares in March; No Capital Changes Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=1185906956","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185906956?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:27","pubTimestamp":1775122027,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Laekna-B (Laekna, Inc.) reported zero movement in both authorised and issued share capital. Authorised Share Capital   • Total authorised shares remained at 5.00...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620025065","title":"BRIEF-Laekna Posts FY Revenue Rmb106.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620025065","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620025065?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:29","pubTimestamp":1773847744,"startTime":"0","endTime":"0","summary":"BRIEF-Laekna Posts FY Revenue Rmb106.7 MillionMarch 18 (Reuters) - Laekna Inc 2105.HK:FY REVENUE RMB106.7 MILLIONLOSS FOR YEAR RMB229.3 MILLIONFurther company coverage: 2105.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620820258","title":"Laekna Narrows Loss in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620820258","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620820258?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:36","pubTimestamp":1773833818,"startTime":"0","endTime":"0","summary":"Laekna  narrowed its loss to 229.3 million yuan for the year 2025 from 254.3 million yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharmaceutical company's loss per share stood at 0.59 yuan, compared with 0.71 yuan in the previous fiscal year.The firm recorded a revenue of 106.7 million yuan in the year, whereas no revenue was seen in the previous year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175483077","title":"LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175483077","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175483077?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:58","pubTimestamp":1773831501,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620321912","title":"Laekna FY2025 net loss narrows 9.8% to CNY229.32 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620321912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620321912?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830590,"startTime":"0","endTime":"0","summary":"Laekna published an annual results announcement for FY 2025, reporting revenue of RMB106.72 million and gross profit of RMB86.42 million. FY 2025 loss for the year narrowed 9.82% to RMB229.32 million, while total comprehensive loss widened 5.51% to RMB253.71 million. R&D expenses rose 16.2% to RMB249.9 million, which Laekna attributed mainly to higher spending on its ActRII portfolio  and increased equity-settled share-based payment expenses. Cash and bank balances increased 95.3% to RMB1.24 billion, and bank loans rose 18.58% to RMB117.41 million. On the pipeline, Laekna said Phase III recruitment for LAE002 plus fulvestrant  in China was completed, with topline data targeted for the first half of 2026, and it also reported Phase I updates for LAE102 and the start of Phase I dosing for LAE103 in Australia.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4cVM64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232198","title":"Laekna Inc -  Loss for Year RMB229.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232198?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830589,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050ZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618026246","title":"Laekna Says Obesity Drug Shows Signs of Lean Body Mass, Reduced Fat in Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2618026246","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618026246?lang=en_us&edition=fundamental","pubTime":"2026-03-10 10:41","pubTimestamp":1773110477,"startTime":"0","endTime":"0","summary":"Laekna  completed the phase 1 single ascending dose study of LAE102, which showed signs of increased lean body mass and reduced fat mass in women, according to a Hong Kong bourse filing Tuesday.After 29 days of treatment, subjects who received the company's drug exhibited a 5.06% increase in mean lean body mass and a 0.12% decrease in mean fat mass from baseline.The study demonstrated a favorable safety profile, with no serious adverse events.The firm said the results add to a \"growing body of data\" supporting the drug's use to treat cardiometabolic diseases. The company is currently planning phase 2 trials of the medicine.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146990437","title":"Laekna-B (02105.HK): Phase I U.S. SAD Study of LAE102 Delivers 5.06% Lean-Mass Gain and Fat-Mass Reduction Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=1146990437","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146990437?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:22","pubTimestamp":1773102178,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (stock code 02105, listed as Laekna-B) released voluntary topline data indicating that its internally discovered monoclonal antibody LAE102 achieved clinically relevant body-composition...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101063129","title":"LAEKNA-B (02105) Reports Encouraging Muscle-Building and Fat-Reducing Trends from US Phase I SAD Study of LAE102","url":"https://stock-news.laohu8.com/highlight/detail?id=1101063129","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101063129?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:20","pubTimestamp":1773102030,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced the successful completion of the Phase I Single Ascending Dose study of LAE102 in the United States, conducted in collaboration with Eli Lilly. The US SAD study was a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180558787","title":"Laekna-B (Stock Code: 02105) Announces Board Meeting Date for Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1180558787","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180558787?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:26","pubTimestamp":1772789186,"startTime":"0","endTime":"0","summary":"Laekna-B (Stock Code: 02105) announced that its board of directors will convene on 18 March 2026 to consider and approve the annual results for the financial year ended 31 December 2025, along with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107428066","title":"Laekna-B (02105) Publishes Monthly Update on Share Capital and Equity Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1107428066","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107428066?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:35","pubTimestamp":1772703311,"startTime":"0","endTime":"0","summary":"Laekna-B (02105) released its monthly equity issuer return for the period ended 28 February 2026, showing that the authorized share capital remains at 5.00 billion ordinary shares with a par value of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199449999","title":"Laekna, Inc. (02105) Announces January 2026 Monthly Return on Movements in Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1199449999","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199449999?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:28","pubTimestamp":1770283723,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (02105) released its monthly return for the period ended January 31, 2026. Authorized share capital remained at 5,000,000,000 ordinary shares, equivalent to US$50,000 in total. The total...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606925300","title":"An Insider At Laekna Lowered Their Holding Recently","url":"https://stock-news.laohu8.com/highlight/detail?id=2606925300","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606925300?lang=en_us&edition=fundamental","pubTime":"2026-01-25 08:09","pubTimestamp":1769299773,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net sellers in Laekna, Inc.'s ( HKG:2105 ) during the past 12 months. That is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/an-insider-at-laekna-lowered-their-holding-recently","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/an-insider-at-laekna-lowered-their-holding-recently","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179784108","title":"LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1179784108","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179784108?lang=en_us&edition=fundamental","pubTime":"2026-01-16 13:44","pubTimestamp":1768542288,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million. The company announced that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132319443","title":"LAEKNA-B (02105) Rises Nearly 7% as FDA Accepts IND Application for New Drug LAE118","url":"https://stock-news.laohu8.com/highlight/detail?id=1132319443","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132319443?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:38","pubTimestamp":1768354704,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) rose nearly 7% during the morning session. At the time of writing, the stock was up 5.88%, trading at HK$14.23 with a turnover of HK$9.34 million. On January 14, LAIKE Medicine...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152771100","title":"LAEKNA-B (02105): US FDA Accepts LAE118 New Drug Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1152771100","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152771100?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:16","pubTimestamp":1768349796,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel, pan-mutant selective PI3Kα...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603599206","title":"FDA Accepts Investigational New Drug Application for Laekna LAE118","url":"https://stock-news.laohu8.com/highlight/detail?id=2603599206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603599206?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:11","pubTimestamp":1768349482,"startTime":"0","endTime":"0","summary":"Laekna Inc. announced that the U.S. Food and Drug Administration  has accepted its Investigational New Drug  application for LAE118, a novel PI3Kα pan-mutant selective inhibitor intended for the treatment of patients with PIK3CA-mutant solid tumors. The company stated it will work closely with regulatory authorities to advance LAE118 into clinical studies. Laekna also cautioned that there is no guarantee the drug will ultimately be successfully developed and commercialized. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2KzY99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595742497","title":"Laekna Doses Subject in LAE103 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2595742497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595742497?lang=en_us&edition=fundamental","pubTime":"2025-12-31 10:50","pubTimestamp":1767149457,"startTime":"0","endTime":"0","summary":"Laekna  said it had dosed the first subject in the phase 1 clinical trial of LAE103, according to  a Hong Kong bourse filing Wednesday.The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103 in overweight or obese subjects.Topline data from the SAD study is expected in the third quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100137130","title":"LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103","url":"https://stock-news.laohu8.com/highlight/detail?id=1100137130","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100137130?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:40","pubTimestamp":1767141623,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia. As...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595745146","title":"Laekna Inc. Doses First Subject in Phase I Trial of LAE103 for Obesity and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745146","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595745146?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:11","pubTimestamp":1767139887,"startTime":"0","endTime":"0","summary":"Laekna Inc. has announced the commencement of a Phase I single ascending dose  clinical study for LAE103, an internally discovered monoclonal antibody targeting ActRIIB. The study is being conducted in Australia and is designed as a randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE103 in healthy overweight or obese participants. According to the company, topline data from this study are expected to be available in the third quarter of 2026. No study results have been presented at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDLBsj03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.1466},{"period":"1month","weight":0.3814},{"period":"3month","weight":0.4106},{"period":"6month","weight":0.2369},{"period":"1year","weight":0.9715},{"period":"ytd","weight":0.3773}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}